Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Show other versions (1)

<p>Abstract</p> <p>Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. <it>Retrovirology </it>2009, 6:25. Since the recent publication of our...

Full description

Bibliographic Details
Main Authors:	Neamati Nouri, Ramkumar Kavya, Odde Srinivas, Serrao Erik
Format:	Article
Language:	English
Published:	BMC 2009-04-01
Series:	Retrovirology
Online Access:	http://www.retrovirology.com/content/6/1/33

Similar Items

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
by: Neamati Nouri, et al.
Published: (2009-03-01)

Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase Inhibitors
by: Kavya Ramkumar, et al.
Published: (2010-06-01)

Raltegravir: first in class HIV integrase inhibitor
by: Zelalem Temesgen, et al.
Published: (2008-06-01)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
by: Yoshimi Enose‐Akahata, et al.
Published: (2021-10-01)

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.
by: Mark A Winters, et al.
Published: (2012-01-01)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
by: de Lejarazu Raul Ortiz, et al.
Published: (2011-06-01)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
by: Goubau Patrick, et al.
Published: (2010-11-01)

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures
by: Hubert Monnerie, et al.
Published: (2023-12-01)

Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
by: Farah F Ammar, et al.
Published: (2012-01-01)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
by: Anthony M. Mills, et al.
Published: (2019-11-01)

Viral Dynamic Model of Antiretroviral Therapy Including the Integrase Inhibitor Raltegravir in Patients with HIV-1
by: Dimitra Bon, et al.
Published: (2012-09-01)

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
by: Narasimha M Midde, et al.
Published: (2016-01-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)

Integrin Targeted Therapeutics
by: Melissa Millard, Srinivas Odde, Nouri Neamati
Published: (2011-01-01)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
by: Lucas de Almeida Machado, et al.
Published: (2019-09-01)

The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
by: Sandrine Reigadas, et al.
Published: (2010-01-01)

#MeToo or "Me Too"?: Defining Our Terms
by: Caitlin Kelly
Published: (2020-11-01)

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
by: Joana Cavaco-Silva, et al.
Published: (2014-01-01)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
by: Aurelio Orta-Resendiz, et al.
Published: (2020-02-01)

Raltegravir monohydrate
by: H. S. Yathirajan, et al.
Published: (2013-12-01)

Design and Synthesis of Bis-amide and Hydrazide-containing Derivatives of Malonic Acid as Potential HIV-1 Integrase Inhibitors
by: Nouri Neamati, et al.
Published: (2008-10-01)

Resistance to Integrase Inhibitors
by: Mathieu Métifiot, et al.
Published: (2010-06-01)

#MeToo, #Travail ?
by: Olivier Cousin, et al.
Published: (2019-11-01)

HIV resistance to raltegravir
by: Clavel François
Published: (2009-11-01)

Biochemical characterization of novel retroviral integrase proteins.
by: Allison Ballandras-Colas, et al.
Published: (2013-01-01)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
by: Hotma Martogi Lorensi Hutapea, et al.
Published: (2018-12-01)

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
by: Pandey KK
Published: (2014-05-01)

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients
by: Margherita Bracchi, et al.
Published: (2021-11-01)

The Epistemic Significance of #MeToo
by: Karyn L Freedman
Published: (2020-06-01)

Raltegravir use in special populations
by: Johnson Margaret
Published: (2009-11-01)

Raltegravir in treatment naïve patients
by: Cossarini F, et al.
Published: (2009-11-01)

Drug-drug interactions with raltegravir
by: Burger David M
Published: (2009-11-01)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
by: Damond Florence, et al.
Published: (2011-08-01)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
by: Pratibha C Koneru, et al.
Published: (2019-05-01)

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
by: Rossana Scutari, et al.
Published: (2020-03-01)

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
by: Geoffrey S Gottlieb, et al.
Published: (2011-01-01)

The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy
by: Sara Rodrigues Fernandes, et al.
Published: (2023-08-01)

Mammutti ja me too -aika
by: Silja Pitkänen
Published: (2023-12-01)

The #MeToo Movement and Ovid's Philomela
by: Justin L. Barker
Published: (2018-01-01)